Her selection leaves the FDA commissioner's post as the only top healthcare job for which Biden hasn't made a pick.
President Joe Biden has picked Chiquita Brooks-LaSure to be his CMS administrator, according to reports today by the Washington Post and Politico.
Brooks-LaSure was reported to be the frontrunner for the job, so this afternoon's news is not a surprise. Both the Post, which broke the story, and the Politico, depended on unnamed sources. Biden has not made an official announcement.
The selection of Brooks-LaSure means that the FDA commissioner's position is last top healthcare job in the new administration for which Biden hasn't made a pick.
Related: Woodcock vs. Sharfstein for FDA Commissioner
Although not well known outside of healthcare policy circles, Brooks-LaSure is fairly well known within them.
She was a senior HHS official during the Obama administration and played a role in implementing and enforcing the rules of the ACA. She also worked on Capitol Hill as a Democratic staffer on the powerful House Ways and Means Committee, according to the Post. She is currently a managing director at Manatt Health.
The Senate confirms CMS administrators so her reported selection by Biden does not mean automatically stepping into the job.
Brooks-LaSure earned a masters in public policy in 1999 and her bachelor’s degree from Princeton in 1996, according to her LinkedIn profile.
Bridging the Diversity Gap in Rare Disease Clinical Trials with Harsha Rajasimha of IndoUSrare
November 8th 2023Briana Contreras, an editor with Managed Healthcare Executive, spoke with Harsha Rajasimha, MD, founder and executive chairman of IndoUSrare, in this month's episode of Tuning in to the C-Suite podcast. The conversation was about how the disparity in diversity and ethnicity in rare disease clinical trials in the U.S. has led to gaps in understanding diseases and conditions, jeopardizing universal health, and increasing the economic burden of healthcare.
Listen
35th World AIDS Day Marks 20 Years of PEPFAR: Challenges and Strategies to Combat HIV/AIDS
November 29th 2023PEPFAR, having invested $100 billion and saved 25 million lives in the global fight against HIV/AIDS, faces Congressional hurdles in its reauthorization due to abortion debates. Despite widespread support and no evidence of abortion-related activities, the legislative process is at a standstill. Members of PEPFAR and authors of a recent editorial stress the significance of PEPFAR and advocate for integrating behavioral and social science into healthcare programs to achieve UNAIDS targets and address barriers in HIV/AIDS testing and treatment.
Read More
Managing Editor of Managed Healthcare Executive, Peter Wehrwein, had a discussion with William Shrank, M.D., a venture partner with Andreessen Horowitz, a venture capital firm in Menlo Park, California, about how artificial intelligence's role is improving healthcare, where we are today with value-based care and the ongoing efforts of reducing waste in the healthcare space for this episode of the "What's on Your Mind" podcast series.
Listen
Study Raises Concerns Over Insurance Barriers to HIV Prevention Medications
November 29th 2023Despite its efficacy, PrEP remains underutilized compared to the need for it. High costs are among the barriers to PrEP use, along with limited knowledge among clinicians, lack of health insurance, stigma, and underestimation of personal HIV risk.
Read More